EPIX Valuation
ESSA Pharma Inc
$
1.730
- Overview
- Forecast
- Valuation
EPIX Relative Valuation
EPIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EPIX is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.65
P/B
Median3y
1.23
Median5y
2.39
-28.51
FCF Yield
Median3y
-17.73
Median5y
-13.27
Competitors Valuation Multiple
The average P/S ratio for EPIX's competitors is 12.04, providing a benchmark for relative valuation. ESSA Pharma Inc Corp (EPIX) exhibits a P/S ratio of 28.05, which is 132.85% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
OTLY
Oatly Group AB (publ)
10.740
USD
-4.36%
KMDA
Kamada Ltd
6.660
USD
+1.37%
CDXS
Codexis Inc
2.520
USD
+8.62%
ZIMV
ZimVie Inc
9.360
USD
+3.54%
NOVA
Sunnova Energy International Inc
0.180
USD
-8.16%
MTRX
Matrix Service Co
12.490
USD
+2.97%
CELC
Celcuity Inc
10.900
USD
+0.93%
AMCX
AMC Networks Inc
6.250
USD
-0.79%
LESL
Leslie's Inc
0.627
USD
0.00%
DHIL
Diamond Hill Investment Group Inc
131.410
USD
+2.11%
FAQ
Is ESSA Pharma Inc (EPIX) currently overvalued or undervalued?
ESSA Pharma Inc (EPIX) is now in the Fair zone, suggesting that its current forward PS ratio of 28.05 is considered Fairly compared with the five-year average of 0.98. The fair price of ESSA Pharma Inc (EPIX) is between to according to relative valuation methord.
What is ESSA Pharma Inc (EPIX) fair value?
How does EPIX's valuation metrics compare to the industry average?
What is the current P/B ratio for ESSA Pharma Inc (EPIX) as of May 04 2025?
What is the current FCF Yield for ESSA Pharma Inc (EPIX) as of May 04 2025?
What is the current Forward P/E ratio for ESSA Pharma Inc (EPIX) as of May 04 2025?